Wells Fargo lowered the firm’s price target on Bluebird Bio to $5 from $8 and keeps an Equal Weight rating on the shares. Bluebird Bio announced that it anticipates 85-105 patient starts in 2024 across Lyfgenia for sickle cell disease, Zynteglo for transfusion-dependent beta-thalassemia and Skysona for cerebral adrenoleukodystrophy, the analyst tells investors in a research note. The price target decrease reflects Lyfgenia approval with a black box warning, resulting in lowered expectations for penetration in SCD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLUE:
- Bluebird in deal with group representing 100M covered lives, after FDA approval
- Bluebird Bio pricing and label concerns are overdone, says Baird
- HSBC gets more bearish on Bluebird Bio, downgrades shares
- CRISPR Therapeutics (NASDAQ:CRSP) Tanks after Analyst Downgrade
- Unusually active option classes on open December 11th
